Abstract
Abemaciclib is the first CDK 4/6 inhibitor to show a significant clinical benefit when added to adjuvant endocrine therapy in patients with high‐risk, node‐positive, HR‐positive, HER2‐negative, early‐stage breast cancer, according to findings from the phase III monarchE trial.